gatipotuzumab
- Generic Name
- gatipotuzumab
CHMP Recommends ENHERTU® Approval for HER2 Low/Ultralow Metastatic Breast Cancer in EU
• The European Medicines Agency's CHMP has recommended approval of ENHERTU® for patients with HER2 low or ultralow metastatic breast cancer who have received prior endocrine therapy.
• This regulatory milestone expands treatment options for metastatic breast cancer patients with lower HER2 expression levels, addressing an important unmet medical need.
• The recommendation follows successful clinical trials demonstrating ENHERTU's efficacy in this patient population, marking a significant advancement in targeted breast cancer therapy.
Daiichi Sankyo Acquires Solid Tumour ADC Gatipotuzumab from Glycotope for $132.5 Million
Daiichi Sankyo has completed the acquisition of gatipotuzumab, an anti-tumour-associated mucin-1 antibody, from Glycotope for $132.5 million. This acquisition, part of a broader licensing agreement, grants Daiichi Sankyo exclusive global rights to develop and commercialize gatipotuzumab as an antibody-drug conjugate (ADC) for treating advanced solid tumours. The move underscores the growing importance of ADCs in oncology, with DS-3939, utilizing gatipotuzumab, currently in Phase I/II clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath